TY - JOUR
T1 - Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents
T2 - A review
AU - Grenier, Michelle A.
AU - Fioravanti, Joanne
AU - Truesdell, Susie C.
AU - Mendelsohn, Alan M.
AU - Vermilion, Roger P.
AU - Lipshultz, Steven E.
N1 - Funding Information:
This review was supported in part by Merck and Company, Whitehouse Station, New Jersey, USA. The opinions expressed in this review are those of the authors and were not influenced by those of Merck and Company, manufacturer of enalapril. The authors would like to thank Drs Paul Lurie, Bradford Berk, Alan Sinaiko, Virginia Frame and Shahnaz Shahinfar for their thoughtful review of this manuscript.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies. Copyright (C) 2000 Elsevier Science Ireland Ltd.
AB - Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies. Copyright (C) 2000 Elsevier Science Ireland Ltd.
KW - ACE inhibition
KW - Afterload reduction
KW - Congenital heart disease
KW - Congestive heart failure
KW - Pediatric
KW - Ventricular dysfunction
UR - http://www.scopus.com/inward/record.url?scp=0033646134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033646134&partnerID=8YFLogxK
U2 - 10.1016/S1058-9813(00)00061-8
DO - 10.1016/S1058-9813(00)00061-8
M3 - Article
AN - SCOPUS:0033646134
VL - 12
SP - 91
EP - 111
JO - Progress in Pediatric Cardiology
JF - Progress in Pediatric Cardiology
SN - 1058-9813
IS - 1
ER -